Suiball has decided to close its Sui ecosystem hardware wallet project despite completing development and starting manufacturing. The company will refund all preorders, with about 80% paid on-chain receiving automatic USD Coin (USDC) refunds within a week. Customers who paid by credit card must provide a Sui wallet address to get their refunds. Suiball will formally shut down the project after all refunds are processed, marking an end to its hardware wallet efforts in the Sui ecosystem.
Suiball's closure of its Sui hardware wallet project provides context for readers interested in the crypto space. For readers following major cryptocurrencies on Pluang, here is a market snapshot as of Nov 12, 2026 05:22 WIB: out of 50 major cryptocurrencies, 27 rose and 22 fell today. Filecoin (FIL) gained 2.97% to Rp13.938 with 100% buy order activity, contrasting with Uniswap (UNI) which fell 3.70% to Rp117.501 and saw 75% sell orders. Stellar (XLM) also rose 2.90% to Rp2.699 with 95% buy orders, showing varied investor interest across these assets.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
